keyword
MENU ▼
Read by QxMD icon Read
search

fibrosis hcv

keyword
https://www.readbyqxmd.com/read/28323868/-waiting-for-daas-a-retrospective-chart-review-of-patients-with-untreated-hepatitis-c-in-rwanda
#1
Neil Gupta, Jules Kabahizi, Constance Mukabatsinda, Timothy David Walker, Emmanuel Musabeyezu, Athanase Kiromera, Jennifer Ilo Van Nuil, Kevin Steiner, Joia Mukherjee, Sabin Nsanzimana, Aimable Mbituyumuremyi
BACKGROUND: Access to treatment for hepatitis C virus (HCV) in sub-Saharan Africa is extremely limited. With the advent of direct acting antivirals (DAAs), highly effective and easy-to-deliver oral regimens are now available on the global market. This study was conducted to understand the background and characteristics of a national cohort of patients with HCV infection enrolled in care and awaiting therapy with DAAs. METHODS AND FINDINGS: We conducted a retrospective chart review of all adult patients with confirmed HCV infection who were currently enrolled in care and treatment at the four existing hepatitis referral centers in Rwanda...
2017: PloS One
https://www.readbyqxmd.com/read/28318046/hepatitis-c-virus-induced-ccl5-secretion-from-macrophages-activates-hepatic-stellate-cells
#2
Reina Sasaki, Pradip B Devhare, Robert Steele, Ranjit Ray, Ratna B Ray
Hepatitis C virus (HCV) mediated chronic liver disease is a serious health problem around the world, and often causes fibrosis/cirrhosis, and hepatocellular carcinoma (HCC). The mechanism of liver disease progression during HCV infection is still unclear, although inflammation is believed to be an important player in disease pathogenesis. We previously reported that macrophages including Kupffer cells exposed to HCV induce proinflammatory cytokines. These secreted cytokines may activate hepatic stellate cells (HSCs) towards fibrosis...
March 20, 2017: Hepatology: Official Journal of the American Association for the Study of Liver Diseases
https://www.readbyqxmd.com/read/28302418/lncrna-atb-microrna-200a-%C3%AE-catenin-regulatory-axis-involved-in-the-progression-of-hcv-related-hepatic-fibrosis
#3
Na Fu, Su-Xian Zhao, Ling-Bo Kong, Jing-Hua Du, Wei-Guang Ren, Fang Han, Qing-Shan Zhang, Wen-Cong Li, Cui Po, Rong-Qi Wang, Yu-Guo Zhang, Yue-Min Nan
OBJECTIVE(S): Long noncoding RNAs (lncRNAs)-activated by transforming growth factor beta (lncRNA-ATB) is known to be involved in the invasion of hepatocellular carcinoma by regulating target gene miR-200a. However, the role and molecular mechanisms of lncRNA-ATB/miR-200a in HCV-related liver fibrosis remains unclear. In this study, we examined the expression of lncRNA-ATB/miR-200a, and their target gene β-Catenin in liver tissues of HCV patients and hepatic stellate cells (HSCs) to elucidate the possible role of lncRNA-ATB/miR-200a axis in HSC activation and development of liver fibrosis...
March 13, 2017: Gene
https://www.readbyqxmd.com/read/28301573/panel-of-three-novel-serum-markers-predicts-liver-stiffness-and-fibrosis-stages-in-patients-with-chronic-liver-disease
#4
Marcin Krawczyk, Simone Zimmermann, Georg Hess, Robert Holz, Marc Dauer, Jochen Raedle, Frank Lammert, Frank Grünhage
Latest data suggest that placental growth factor (PLGF), growth differentiation factor-15 (GDF-15) and hepatic growth factor (HGF) are involved in hepatic fibrogenesis. Diagnostic performance of these markers for non-invasive liver fibrosis prediction was evaluated based on liver histology and stiffness. In total 834 patients were recruited. Receiver-operating-characteristics were used to define cut-offs for markers correlating to fibrosis stages. Odds-ratios were calculated for the presence/absence of fibrosis/cirrhosis and confirmed in the sub-group of patients phenotyped by elastography only...
2017: PloS One
https://www.readbyqxmd.com/read/28299813/improvement-of-liver-stiffness-in-patients-with-hepatitis-c-virus-infection-who-received-direct-acting-antiviral-therapy-and-achieved-sustained-virological-response
#5
Toshifumi Tada, Takashi Kumada, Hidenori Toyoda, Kazuyuki Mizuno, Yasuhiro Sone, Saki Kataoka, Shinichi Hashinokuchi
BACKGROUND AND AIM: There is insufficient research on whether direct-acting antiviral (DAA) therapy can improve liver fibrosis in patients with chronic hepatitis C virus (HCV). We evaluated sequential changes in liver stiffness using shear wave elastography (SWE) in patients with HCV who received DAA therapy. METHODS: A total of 210 patients with HCV who received daclatasvir and asunaprevir therapy and achieved sustained virological response (SVR) were analyzed...
March 15, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28288626/hepatitis-c-related-hepatocellular-carcinoma-in-the-era-of-new-generation-antivirals
#6
REVIEW
Thomas F Baumert, Frank Jühling, Atsushi Ono, Yujin Hoshida
Hepatitis C virus infection is a major cause of hepatocellular carcinoma worldwide. Interferon has been the major antiviral treatment, yielding viral clearance in approximately half of patients. New direct-acting antivirals substantially improved the cure rate to above 90%. However, access to therapies remains limited due to the high costs and under-diagnosis of infection in specific subpopulations, e.g., baby boomers, inmates, and injection drug users, and therefore, hepatocellular carcinoma incidence is predicted to increase in the next decades even in high-resource countries...
March 14, 2017: BMC Medicine
https://www.readbyqxmd.com/read/28286290/the-effect-of-the-hepatitis-c-virus-hcv-ns3-protein-on-the-expression-of-mir-150-mir-199a-mir-335-mir-194-and-mir-27a
#7
Sayyad Khanizadeh, Mehrdad Ravanshad, Seyed Younes Hosseini, Parivash Davoodian, Mohammad Almasian, Zahra Khanlari
Hepatitis C virus (HCV) infection is considered one of the most important causes of chronic liver diseases. Many reports have shown that the proteins of the HCV via interactions with gene expression regulatory networks such as cellular pathways and microRNAs can contribute to the development of chronic liver diseases. The present study aimed to investigate the effects of the HCV NS3 protein on the expression of miR-150 miR-199a, miR-335, miR-194, miR-27a in a cell culture model. Plasmids expressing the full length of the HCV NS3 protein were transfected into the LX-2 cell line, while at the same time a plasmid expressing empty GFP (green fluorescent protein) was used as a negative control group...
March 9, 2017: Microbial Pathogenesis
https://www.readbyqxmd.com/read/28280374/optimizing-choice-of-oral-interferon-free-treatment-for-genotype-1-hepatitis-c-virus-using-testing-for-ns5a-resistance-a-cost-utility-analysis-from-the-perspective-of-the-italian-national-health-service
#8
Kirsten Y Westerhout, Walter Bouwmeester, Inge Duchesne, Marta Pisini, Marjanne A Piena, Francesco Damele, Beatrice Gueron, Maarten Treur, Jonathan Belsey
BACKGROUND: Patients with genotype-1 hepatitis C virus infection who have failed to respond to standard therapy or who relapse following treatment may be considered for an interferon-free regimen incorporating a nonstructural protein 5A (NS5A) inhibitor. Sustained virologic response (SVR) with these regimens is typically >90%, but this is reduced in patients with NS5A resistance. European Association for Study of the Liver guidelines recommend simeprevir + sofosbuvir ± ribavirin (SMV+SOF±R) for re-treating patients failing an NS5A inhibitor-containing regimen...
2017: ClinicoEconomics and Outcomes Research: CEOR
https://www.readbyqxmd.com/read/28271684/methylene-tetrahydrofolate-reductase-gene-polymorphism-is-associated-with-severity-of-liver-steatosis-in-chronically-infected-patients-with-hcv-genotype-4
#9
Reham M Dawood, Eman M Mahmoud, Marwa K Ibrahim, Noha G Bader El Din, Ahmed Aboul-Enein, Naglaa Zayed, Yasmine S El Abd, Hadeel G Eldeen, Rasha Eletreby, Marwa Elsharkawy, Moataza Omran, Reem El-Shenawy, Sayed A Fayed, Mostafa K El Awady
BACKGROUND: Methylene tetrahydrofolate reductase (MTHFR) C677T polymorphism was reported as a genetic variant in liver steatosis and fibrosis. This is a study of the association between MTHFR C677T polymorphism and HCV core with severity of steatosis in HCV GT4 patients. METHODS: 111 HCV patients and 112 control subjects were recruited. Polymorphism was detected by RFLP analysis, core Ag was detected by ELISA. RESULTS: Combined HCV infection and MTHFR C677T polymorphism increases the risk to develop steatosis by 3...
March 1, 2017: Clinical Laboratory
https://www.readbyqxmd.com/read/28270038/inf-free-sofosbuvir-based-treatment-of-post-transplant-hepatitis-c-relapse-a-swedish-real-life-experience
#10
Castedal Maria, Segenmark Michael, Cederberg Susanne, Skoglund Catarina, Weiland Ola
BACKGROUND: Relapse of hepatitis C virus (HCV) infection after liver transplantation has been universal, and the fibrosis progression faster than in non-transplanted patients. Interferon (IFN)-free treatment with direct antiviral agents (DAA) has improved the treatment outcome dramatically. We here report on the outcome of IFN-free treatment for HCV relapse after liver transplantation in a real life setting in Sweden. MATERIAL: In total, 93 patients with a mean age of 60 years (range 32-80) with HCV relapse after liver transplantation were given sofosbuvir-based treatment in combination with a protease inhibitor (simeprevir) or a NS5A inhibitor (daclatasvir or ledipasvir) with or without addition of ribavirin (RBV), or sofosbuvir and RBV only...
May 2017: Scandinavian Journal of Gastroenterology
https://www.readbyqxmd.com/read/28267407/the-evolving-relationship-between-adiponectin-and-insulin-sensitivity-in-hepatitis-c-patients-during-viral-clearance
#11
Ming-Ling Chang, Chia-Jung Kuo, Li-Heng Pao, Chen-Ming Hsu, Cheng-Tang Chiu
BACKGROUND: The evolution of the relationship between adiponectin and insulin sensitivity in hepatitis C virus (HCV) patients during viral clearance is unclear and warrants investigation. METHODS: A prospective study including 747 consecutive chronic hepatitis C (CHC) patients, of whom 546 had completed a course of anti-HCV therapy and underwent pre-, peri- and post-therapy surveys for anthropomorphic, viral, metabolic and hepatic profiles and adiponectin levels, was conducted in a tertiary care center...
March 7, 2017: Virulence
https://www.readbyqxmd.com/read/28263455/liver-disease-and-fibrosis-assessment-in-substance-use-related-disorders
#12
Marija Zeremski, Anthony Martinez
Substance users have the highest prevalence of hepatitis C virus (HCV) infection but have rarely been treated, largely because of their mistrust of the health care system, misconceptions about the consequences of the infection, and concerns regarding interferon-related side effects. With the development of highly efficacious, interferon-free therapeutic regimens without significant side effects, the concept of colocating HCV and substance use treatment would appear to be highly feasible. This process has been further facilitated by widespread clinical adaptation of noninvasive assays for fibrosis assessment, which could be performed routinely in substance use treatment facilities...
March 2017: Clinical Pharmacology in Drug Development
https://www.readbyqxmd.com/read/28262531/non-invasive-assessment-of-liver-fibrosis-in-patients-with-hepatitis-c-shear-wave-elastography-and-colour-doppler-velocity-profile-technique-versus-liver-biopsy
#13
Ehab F Moustafa, Nahed Makhlouf, Sahar M Hassany, Ahmed Helmy, Ahmed Nasr, Moustafa Othman, Hany Seif, Manal Darwish, Howayda Hassan, Mohamed Hessen
BACKGROUND AND STUDY AIMS: Determination of the presence and degree of liver fibrosis is essential for the prognosis and treatment of patients with chronic hepatitis C. Non-invasive methods of assessing fibrosis have been developed to reduce the need for biopsy. We determined the efficacy of shear wave elastography (SWE) and colour Doppler velocity as non-invasive methods for the assessment of liver fibrosis compared to liver biopsy among patients with chronic hepatitis C virus (HCV) infection...
March 2, 2017: Arab Journal of Gastroenterology: the Official Publication of the Pan-Arab Association of Gastroenterology
https://www.readbyqxmd.com/read/28261385/influence-of-vitamin-d-on-liver-fibrosis-in-chronic-hepatitis-c-a-systematic-review-and-meta-analysis-of-the-pooled-clinical-trials-data
#14
Alia S Dadabhai, Behnam Saberi, Katie Lobner, Russell T Shinohara, Gerard E Mullin
AIM: To investigate the relationship between vitamin D and liver fibrosis in hepatitis C-monoinfected or hepatitis C virus (HCV)-human immunodeficiency virus (HIV) co-infected patients. METHODS: Pertinent studies were located by a library literature search in PubMed/Embase/Cochrane/Scopus/LILACS by two individual reviewers. Inclusion criteria: (1) studies with patients with HCV or co-infected HCV/HIV; (2) studies with patients ≥ 18 years old; (3) studies that evaluated liver fibrosis stage, only based on liver biopsy; and (4) studies that reported serum or plasma 25(OH)D levels...
February 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28260862/sofosbuvir-velpatasvir-regimen-promises-an-effective-pan-genotypic-hepatitis-c-virus-cure
#15
REVIEW
Fazia Mir, Alp S Kahveci, Jamal A Ibdah, Veysel Tahan
Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide. HCV is the most common blood-borne infection in the US with numerous health implications including liver fibrosis, cirrhosis, and hepatocellular cancer. Traditional genotype-based HCV therapies with interferon resulted in moderate success in the sustained elimination of viral genome. Recent clinical trials of the once-daily combination tablet of sofosbuvir, a nonstructural (NS) 5B polymerase inhibitor, and velpatasvir, an NS5A inhibitor, demonstrate sustained virologic response rates of about 95%, regardless of prior treatment experience or presence of cirrhosis across all HCV genotypes...
2017: Drug Design, Development and Therapy
https://www.readbyqxmd.com/read/28258770/effectiveness-of-paritaprevir-ritonavir-ombitasvir-dasabuvir-in-hemodialysis-patients-with-hepatitis-c-virus-infection-and-advanced-liver-fibrosis-case-reports
#16
Francesca Romana Ponziani, Massimo Siciliano, Raffaella Lionetti, Caterina Pasquazzi, Laura Gianserra, Gianpiero D'Offizi, Antonio Gasbarrini, Maurizio Pompili
Hepatitis C virus infection is common among patients on hemodialysis therapy and is an important cause of morbidity and mortality. We investigated the safety and effectiveness of a paritaprevir/ritonavir/ombitasvir/dasabuvir regimen in a group of 10 patients on hemodialysis therapy with genotype 1a, 1b, or 4 hepatitis C virus infection who had predictors of unfavorable response, such as compensated cirrhosis (7 patients) or advanced fibrosis and failure of previous therapy (3 patients). The treatment, with or without ribavirin, was administered daily for 12 or 24 weeks...
March 1, 2017: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://www.readbyqxmd.com/read/28258705/daclatasvir-and-asunaprevir-treatment-in-patients-with-severe-liver-fibrosis-by-hcv-genotype-1b-infection-real-world-data
#17
Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Teiji Kuzuya, Yoji Ishizu, Tetsuya Ishikawa, Isao Nakano, Fumihiro Urano, Takashi Kumada, Kentaro Yoshioka, Hidemi Goto, Yoshiki Hirooka
BACKGROUNDS AND AIMS: In this study, we investigated the real-world data of the first approved interferon free regimen in Japan; daclatasvir as asunaprevir in chronic hepatitis C patients with severe fibrosis. PATIENTS AND METHODS: Among 924 patients registered in our multicenter study, 535 patients were defined as having severe fibrosis with Fib-4 index≧3.25, and were included in this study. We investigated anti-viral effect and factors associated with SVR12, and the additional effects on serum AFP and albumin levels by eradicating virus in patients who attained SVR were investigated...
March 4, 2017: Journal of Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/28254091/a-methodology-for-automated-cpa-extraction-using-liver-biopsy-image-analysis-and-machine-learning-techniques
#18
Markos G Tsipouras, Nikolaos Giannakeas, Alexandros T Tzallas, Zoe E Tsianou, Pinelopi Manousou, Andrew Hall, Ioannis Tsoulos, Epameinondas Tsianos
BACKGROUND AND OBJECTIVE: Collagen proportional area (CPA) extraction in liver biopsy images provides the degree of fibrosis expansion in liver tissue, which is the most characteristic histological alteration in hepatitis C virus (HCV). Assessment of the fibrotic tissue is currently based on semiquantitative staging scores such as Ishak and Metavir. Since its introduction as a fibrotic tissue assessment technique, CPA calculation based on image analysis techniques has proven to be more accurate than semiquantitative scores...
March 2017: Computer Methods and Programs in Biomedicine
https://www.readbyqxmd.com/read/28250290/the-relationship-between-the-growth-hormone-insulin-like-growth-factor-system-and-the-histological-features-of-nonalcoholic-fatty-liver-disease
#19
Sayaka Chishima, Tomomi Kogiso, Noriko Matsushita, Etsuko Hashimoto, Katsutoshi Tokushige
Objective Growth hormone (GH) deficiency has recently been reported as a cause of nonalcoholic fatty liver disease (NAFLD), and GH supplementation has been shown to improve the histology of NAFLD. The aim of the present study was to clarify the relationship between the histological severity of NAFLD and production of the GH/insulin-like growth factor 1 (IGF-1) axis. Methods A total of 222 Japanese patients with liver biopsy-confirmed NAFLD and 55 patients with hepatitis C virus (HCV)-related chronic liver disease (CLD) were enrolled in the present study...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28245654/treating-medicaid-patients-with-hepatitis-c-clinical-and-economic-impact
#20
Zobair Younossi, Stuart C Gordon, Aijaz Ahmed, Douglas Dieterich, Sammy Saab, Rachel Beckerman
OBJECTIVES: To estimate change in chronic hepatitis C virus (HCV) disease and the economic burden associated with comprehensive treatment of the chronic HCV-infected Medicaid population. STUDY DESIGN: Decision-analytic Markov model. METHODS: Treatment-naïve patients with genotype 1 chronic HCV were followed over a lifetime horizon from the third-party payer perspective. Patients entered the model insured under Medicaid and were treated under state-specific restrictions by Metavir fibrosis stage (base case) or all treated (all-patient strategy) with an approved all-oral regimen (ledipasvir/sofosbuvir [LDV/SOF] for 8 weeks or 12 weeks, depending on cirrhosis status, viral load, and state-specific LDV/SOF restrictions)...
February 2017: American Journal of Managed Care
keyword
keyword
94653
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"